All content for Retinal Physician Insider is the property of Retinal Physician Insider and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Peter Kaiser, MD and Judy Kim, MD discuss DRCR and key findings from recent protocols.
Peter Kaiser, MD, and Jeffrey Heier, MD, examine the findings of the Novartis-appointed Safety Review Committee’s independent assessment of post-marketing cases of inflammation following the approval of brolucizumab.
Retinal Physician Insider
Peter Kaiser, MD and Judy Kim, MD discuss DRCR and key findings from recent protocols.
